Thirdly, This meta-analysis showed SGLT2 inhibitors can reduce average 1.42kg body weight in adults with overweight or obesity but not diabetes, but the clinical and prognostic benefit of weight change were limited base on the previous studies (34–36). The gene discussed is SLC5A2; the disease is Obesity.